Utilisation of the ESMO-MCBS in practice of HTA

C. Wild, N. Grössmann, P. V. Bonanno, A. Bucsics, J. Furst, K. Garuoliene, B. Godman, J. Gulbinovič, J. Jones, M. K. Pomorski, R. Emprechtinger

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

It is highly appreciated that the European Society of Medical Oncology has developed a system to assess new oncologic compounds according to their value to patients. Consequently, offering decision-support to those who either want to use the new cancer therapies in clinical practice but cannot keep up-to-date with all therapy options or, alternatively, to those who have to decide whether or not to fund new oncology medicines or exclude from reimbursement due to their low value. This is particularly important with ever-rising prices for new oncology medicines which have increased up to ten fold in recent years.
LanguageEnglish
Pages2134-2136
Number of pages3
JournalAnnals of Oncology
Volume27
Issue number11
Early online date8 Aug 2016
DOIs
Publication statusPublished - 30 Nov 2016

Fingerprint

Medical Oncology
Financial Management
Therapeutics
Neoplasms

Keywords

  • oncology
  • cancer therapies
  • clinical practice
  • oncology medicines

Cite this

Wild, C., Grössmann, N., Bonanno, P. V., Bucsics, A., Furst, J., Garuoliene, K., ... Emprechtinger, R. (2016). Utilisation of the ESMO-MCBS in practice of HTA. Annals of Oncology, 27(11), 2134-2136. https://doi.org/10.1093/annonc/mdw297
Wild, C. ; Grössmann, N. ; Bonanno, P. V. ; Bucsics, A. ; Furst, J. ; Garuoliene, K. ; Godman, B. ; Gulbinovič, J. ; Jones, J. ; Pomorski, M. K. ; Emprechtinger, R. / Utilisation of the ESMO-MCBS in practice of HTA. In: Annals of Oncology. 2016 ; Vol. 27, No. 11. pp. 2134-2136.
@article{f39a20857aec4ac288d2f0616eeae8d7,
title = "Utilisation of the ESMO-MCBS in practice of HTA",
abstract = "It is highly appreciated that the European Society of Medical Oncology has developed a system to assess new oncologic compounds according to their value to patients. Consequently, offering decision-support to those who either want to use the new cancer therapies in clinical practice but cannot keep up-to-date with all therapy options or, alternatively, to those who have to decide whether or not to fund new oncology medicines or exclude from reimbursement due to their low value. This is particularly important with ever-rising prices for new oncology medicines which have increased up to ten fold in recent years.",
keywords = "oncology, cancer therapies, clinical practice, oncology medicines",
author = "C. Wild and N. Gr{\"o}ssmann and Bonanno, {P. V.} and A. Bucsics and J. Furst and K. Garuoliene and B. Godman and J. Gulbinovič and J. Jones and Pomorski, {M. K.} and R. Emprechtinger",
year = "2016",
month = "11",
day = "30",
doi = "10.1093/annonc/mdw297",
language = "English",
volume = "27",
pages = "2134--2136",
journal = "Annals of Oncology",
issn = "1569-8041",
number = "11",

}

Wild, C, Grössmann, N, Bonanno, PV, Bucsics, A, Furst, J, Garuoliene, K, Godman, B, Gulbinovič, J, Jones, J, Pomorski, MK & Emprechtinger, R 2016, 'Utilisation of the ESMO-MCBS in practice of HTA' Annals of Oncology, vol. 27, no. 11, pp. 2134-2136. https://doi.org/10.1093/annonc/mdw297

Utilisation of the ESMO-MCBS in practice of HTA. / Wild, C.; Grössmann, N.; Bonanno, P. V.; Bucsics, A.; Furst, J.; Garuoliene, K.; Godman, B.; Gulbinovič, J.; Jones, J.; Pomorski, M. K.; Emprechtinger, R.

In: Annals of Oncology, Vol. 27, No. 11, 30.11.2016, p. 2134-2136.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Utilisation of the ESMO-MCBS in practice of HTA

AU - Wild, C.

AU - Grössmann, N.

AU - Bonanno, P. V.

AU - Bucsics, A.

AU - Furst, J.

AU - Garuoliene, K.

AU - Godman, B.

AU - Gulbinovič, J.

AU - Jones, J.

AU - Pomorski, M. K.

AU - Emprechtinger, R.

PY - 2016/11/30

Y1 - 2016/11/30

N2 - It is highly appreciated that the European Society of Medical Oncology has developed a system to assess new oncologic compounds according to their value to patients. Consequently, offering decision-support to those who either want to use the new cancer therapies in clinical practice but cannot keep up-to-date with all therapy options or, alternatively, to those who have to decide whether or not to fund new oncology medicines or exclude from reimbursement due to their low value. This is particularly important with ever-rising prices for new oncology medicines which have increased up to ten fold in recent years.

AB - It is highly appreciated that the European Society of Medical Oncology has developed a system to assess new oncologic compounds according to their value to patients. Consequently, offering decision-support to those who either want to use the new cancer therapies in clinical practice but cannot keep up-to-date with all therapy options or, alternatively, to those who have to decide whether or not to fund new oncology medicines or exclude from reimbursement due to their low value. This is particularly important with ever-rising prices for new oncology medicines which have increased up to ten fold in recent years.

KW - oncology

KW - cancer therapies

KW - clinical practice

KW - oncology medicines

UR - https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdw297

U2 - 10.1093/annonc/mdw297

DO - 10.1093/annonc/mdw297

M3 - Article

VL - 27

SP - 2134

EP - 2136

JO - Annals of Oncology

T2 - Annals of Oncology

JF - Annals of Oncology

SN - 1569-8041

IS - 11

ER -

Wild C, Grössmann N, Bonanno PV, Bucsics A, Furst J, Garuoliene K et al. Utilisation of the ESMO-MCBS in practice of HTA. Annals of Oncology. 2016 Nov 30;27(11):2134-2136. https://doi.org/10.1093/annonc/mdw297